Scientists from the lab of Professor David Schubert, including first author Antonio Currais and co-corresponding author Pamela Maher, have shown how the Alzheimer’s drug candidates CMS121 and J147 can slow aging in healthy older mice, blocking the damage to brain cells that normally occurs during aging and restoring the levels of specific molecules to those seen in younger brains. The research points out a new pathway that links normal aging to Alzheimer’s disease.Read News Release
Diabetes drug has unexpected, broad implications for healthy aging
Metformin is the most commonly prescribed type 2 diabetes drug, yet scientists still do not fully know how it works to control blood sugar levels. Professor Reuben Shaw, director of Salk’s NCI-designated Cancer Center, and collaborators have used a novel technology to investigate why it functions so well. The findings, which identified a surprising number of biochemical “switches” for various cellular processes, could also explain why metformin has been shown in recent studies to extend health span and life span.Read News Release
Drug combo reverses arthritis in rats
People with osteoarthritis, or “wear and tear” arthritis, have limited treatment options: pain relievers or joint replacement surgery. Research co-led by Professor Juan Carlos Izpisua Belmonte and Salk co-first authors Paloma Martinez-Redondo and Isabel Guillen-Guillen, has discovered that a powerful combination of two experimental drugs reverses the cellular and molecular signs of osteoarthritis in rats as well as in isolated human cartilage cells.Read News Release
- Apart but togetherAs COVID-19 spreads across the world, organizations like the Salk Institute have mobilized to respond. In this feature article, read about how the Institute is adapting and continuing its groundbreaking science.
- New COVID-19 research projectsIn addition to Salk’s ongoing research areas relevant to COVID-19, several new coronavirus-specific projects have recently launched. These innovative projects range from understanding the structure of the virus to mobilizing the body’s immune reaction.
- A conversation with Martin HetzerIn the last few months, Salk Vice President and Chief Science Officer Martin Hetzer spearheaded the Institute’s efforts to respond to the pandemic from both an administrative as well as a scientific perspective.
- Eiman Azim – Decoding dexterityIn this Q&A, Assistant Professor Eiman Azim shares his thoughts on what’s next in neuroscience, how all scientists are philosophers and what he learned about movement from observing his newborn.
- Nasun Hah – Next gen sequencingAs the director of the Next Generation Sequencing Core, Staff Scientist Nasun Hah collaborates with everyone from plant biologists to neuroscientists to provide support and information about sequencing genes and entire genomes.
- Update on initiatives to support diversity and BIPOCLearn about the Institute’s commitment to and actions around diversity and inclusion.
- Molly MattyMolly Matty, a postdoctoral researcher in the lab of Associate Professor Shrek Chalasani, shares what worms can teach us about human behavior, why science outreach is so important and why she enjoys puns.